一名正在接受ravulizumab治疗阵发性夜间血红蛋白尿（PNH）的患者感染了新冠病毒。
COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab.
作者信息
Shikdar Sufana, Borogovac Azra, Mohamad Elabdallah, Khawandanah Mohamad
机构信息
Department of Hematology/Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 73104, Oklahoma City, United States, OK.
Hematology/Oncology fellow, Department of Medicine, Division of Hematology-Oncology Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 800 NE 10th St., 6th Floor, OK, 73104, Oklahoma City, United States.
出版信息
Thromb J. 2021 Oct 21;19(1):75. doi: 10.1186/s12959-021-00330-6.
BACKGROUND
In the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in this subgroup.
CASE PRESENTATION
We describe a case of a 32-year-old man with paroxysmal nocturnal hemoglobinuria (PNH) undergoing treatment with ravulizumab (Ultomiris) who presented with COVID19 infection. He experienced only mild symptoms and had a rapid recovery from COVID19 infection.
CONCLUSION
This case may demonstrate the beneficial effects of ravulizumab on complement mediated inflammatory damage linked with COVID19 infection especially in PNH patients.
背景
在最近的新冠疫情中，血液系统疾病患者被认为是重症疾病的高危人群。关于该亚组患者新冠病毒感染病程的数据有限。
病例报告
我们描述了一例32岁阵发性夜间血红蛋白尿（PNH）患者，正在接受ravulizumab（Ultomiris）治疗，该患者感染了新冠病毒。他仅出现轻微症状，且从新冠病毒感染中迅速康复。
结论
该病例可能证明了ravulizumab对与新冠病毒感染相关的补体介导的炎症损伤具有有益作用，尤其是在PNH患者中。
Zotero 插件